Tilray surged Wednesday alongside Canopy Growth and Aurora Cannabis, but one number from 2026 tells a very different story about why today's rally leaves the real problem untouched.

Cannabis consolidation appears to be accelerating.

Revenue grew 13% as MTL integration and Polish market strength drove results.

Curaleaf is attempting to acquire Canopy Growth's rival, Aurora Cannabis, and there could be more consolidation to come in the industry.

Canopy Growth (NASDAQ:CGC) is positioning itself for further expansion in medical cannabis, European markets and Canadian recreational cannabis after restructuring operations, reducing costs and acquiring MTL Cannabis, President and CEO Luc Mongeau said during a Canaccord Genuity presentation. Mong

The turnaround is becoming more believable.

Canopy Growth Corp (CGC) reports broad-based growth across all segments, with adjusted EBITDA loss improving 59% year-over-year.

Key Takeaways; Cannabis Sector Canopy Growth Posted 13% Revenue Growth as Losses Narrowed Sharply in Q1 FY2027 Aurora Cannabis Narrowed Q1 Loss as International Medical Cannabis Growth Gained Ground Cronos Group Reported Record Q2 Revenue as Profitability and EBITDA Surged Key Takeaways; Psychedelic Sector Compass Pathways is Building Momentum Toward Potential COMP360 Launch as Veterans […]

Download the Complete Report Here Aurora Cannabis Inc. (ACB) International Medical Growth Absorbs Much of Canadian Pricing Reset; Safari and Germany Momentum Strengthen the Medium-Term Growth Outlook. Attractively Valued. Key Takeaways: International medical cannabis revenue increased 17% to C$43.3 million in 1Q FY27, reinforcing ACB’s leadership across global medical markets. Adjusted gross margin reached 58%, […] The post Why Aurora Cannabis Looks Cheaper Than Its International Growth Suggests

Canopy Growth is a marijuana stock, but U.S. regulations aren't the main driver of its business.

Canopy Growth (NASDAQ:CGC) reported first-quarter fiscal 2027 net revenue of C$81.2 million, up 13% from the prior-year period, as the company recorded year-over-year growth across its cannabis and Storz & Bickel businesses. Chief Executive Officer Luc Mongeau said the quarter marked the first

Canopy Growth Corporation (TSX:WEED, NYSE:CGC) reported continued revenue growth across its businesses in the first quarter of fiscal 2027, while the cannabis company narrowed its adjusted EBITDA loss from a year earlier, sending its shares 5% higher on Friday morning. Net revenue for the...

Canopy Growth (CGC) delivered earnings and revenue surprises of +50.00% and +0.20%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Both readings are true at once, and the gap between them is the real question for anyone weighing the shares.

The next key catalyst for this cannabis stock lies in the hands of a U.S. Federal Government agency.

Canopy Growth Corporation (CGC) reached $0.89 at the closing of the latest trading day, reflecting a -1.82% change compared to its last close.

The latest trading day saw Canopy Growth Corporation (CGC) settling at $0.91, representing a -2.67% change from its previous close.

Canopy Growth (CGC) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.

The president directed federal authorities to reschedule medical marijuana.

The latest trading day saw Canopy Growth Corporation (CGC) settling at $0.96, representing a -1.15% change from its previous close.